SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ICCC

ImmuCell Corporation (NASDAQ:ICCC)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$10.75+$0.53 (+5.19%)
 
Market cap
$97.6M
Insider Score
Health Score
Listed since
May 5, 1987
Market Cap$97.63M+77.7%
Revenue (ttm)$33.21M+19.6%
Net Income$1.88M-19.1%
EPS$0.20-22.4%
Shares Out9.08M
PE Ratio53.75
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,422
Open$10.66
Previous Close$10.22
Day's Range$10.50 - $10.75
52-Week Range$4.52 - $12.10
Beta0.62
Analystsn/a
Price Targetn/a
Earnings DateFeb 23, 2027
+5.19% (1D)
No price history available.

About ICCC

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

Address
56 Evergreen Drive, Portland, ME, 04103, US
Market Cap
98 million
Employees
73
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$75.96K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From ICCC’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+5.19%
5 Days
+8.04%
1 Month
-0.37%
6 Months
+28.59%
1 Year
+77.69%

$ICCC stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ICCC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ICCC's directors and management

Net Shares Purchased by Insiders−8k−4k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ICCC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ICCC Revenue by Segment

$12.52MTotal
Product sales$8.04M64.19%
Costs of goods sold$4.48M35.81%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ICCC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ICCC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ICCC

VTIVanguard Morningstar Total Stock Market ETF$1.77M
VXFVanguard Extended Market ETF$774.07K
IWCiShares Micro-Cap ETF$195.16K
DFACDimensional - US Core Equity 2 ETF$188.43K
DFATDimensional - US Targeted Value ETF$76.71K
DXUVU.S. Vector Equity Portfolio ETF Class Shares$30.54K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ICCC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
No data yet
—
News & Sentiment
100% of score
72

News check: Strong Q3 sales growth of 46% demonstrates solid business momentum; preliminary earnings beat expectations with notable revenue increase.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$75.96K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.